Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Lushang Freda Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600223'
s EV-to-FCF Range Over the Past 10 Years
Min: -294.11 Med: 4.19 Max: 628.91
Current: 13.69
During the past 13 years, the highest EV-to-FCF of Lushang Freda Pharmaceutical Co was 628.91. The lowest was -294.11. And the median was 4.19.
SHSE:600223's EV-to-FCF is ranked better than 60.44% of 1092
companies
in the Real Estate industry
Industry Median: 18.91
vs SHSE:600223: 13.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lushang Freda Pharmaceutical Co (SHSE:600223) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lushang Freda Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Lushang Freda Pharmaceutical Co's share price for today is ¥5.52.
Lushang Freda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lushang Freda Pharmaceutical Co EV-to-FCF Related Terms
Lushang Freda Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co EV-to-FCF Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co EV-to-FCF vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's EV-to-FCF falls into.
Lushang Freda Pharmaceutical Co's current Enterprise Value is ¥3,676 Mil.
Lushang Freda Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a EV-to-FCF of 13.69 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 227% above median its historical median of 4.19. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #432 out of 1092 companies in the Real Estate industry, placing it in the top 39.6%.
Is Lushang Freda Pharmaceutical Co's EV-to-FCF too high?
Lushang Freda Pharmaceutical Co's current EV-to-FCF of 13.69 is 227% above median its 10-year median of 4.19. The Real Estate industry median EV-to-FCF is 18.91. Lushang Freda Pharmaceutical Co's value of 13.69 is 27.6% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #432 out of 1092 companies in the Real Estate industry, which is above the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's EV-to-FCF compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #432 out of 1092 companies for EV-to-FCF. This puts Lushang Freda Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 18.91. Lushang Freda Pharmaceutical Co's value of 13.69 is 27.6% below this benchmark. While the company's 10-year median is 4.19 vs. the industry median of 18.91, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Real Estate company?
The median EV-to-FCF among Real Estate companies is 18.91, based on 1,092 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current EV-to-FCF of 13.69 is 27.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median EV-to-FCF is 18.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current EV-to-FCF is 13.69, which is 227% above median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.57, compared to a current price of ¥5.52 — trading 16% below its estimated fair value. The current EV-to-FCF is 13.69, which is 227% above median its 10-year median of 4.19 and 27.6% below the Real Estate industry median of 18.91. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current EV-to-FCF is 13.69 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.52 is trading 16% below its estimated GF Value™ of ¥6.57.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
EV-to-FCF: 13.69 (227% above median its 10-year median of 4.19)
GF Value™: ¥6.57 vs. price of ¥5.52 (16% below fair value)
Industry Position: 27.6% below the Real Estate median (#432 of 1092)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score
Get the complete analysis for SHSE:600223
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
